ORIONS Money Stocks

[AugustaFriends]

Inhibitex initiated with a Outperform at Wedbush; tgt $9: . Wedbush initiates INHX with a Outperform and price target of $9 based on the conviction that Inhibitex could attract a high profile partnership or be an acquisition candidate. Firm notes INHX is developing one of only two later-clinical stage HCV drug candidates in the sought-after class of nucleotides which is not owned by or partnered to big pharma.